JP2020527545A - 標的化送達のための磁性ナノ粒子 - Google Patents

標的化送達のための磁性ナノ粒子 Download PDF

Info

Publication number
JP2020527545A
JP2020527545A JP2019572658A JP2019572658A JP2020527545A JP 2020527545 A JP2020527545 A JP 2020527545A JP 2019572658 A JP2019572658 A JP 2019572658A JP 2019572658 A JP2019572658 A JP 2019572658A JP 2020527545 A JP2020527545 A JP 2020527545A
Authority
JP
Japan
Prior art keywords
nanoparticles
magnetic
plga
therapeutic agent
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019572658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527545A5 (https=
Inventor
シャピロ，ベンジャミン
シュコール，モハメッド
Original Assignee
オトマグネティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オトマグネティクス，インコーポレイテッド filed Critical オトマグネティクス，インコーポレイテッド
Publication of JP2020527545A publication Critical patent/JP2020527545A/ja
Publication of JP2020527545A5 publication Critical patent/JP2020527545A5/ja
Priority to JP2023204132A priority Critical patent/JP2024028827A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019572658A 2017-06-30 2018-06-30 標的化送達のための磁性ナノ粒子 Pending JP2020527545A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204132A JP2024028827A (ja) 2017-06-30 2023-12-01 標的化送達のための磁性ナノ粒子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527274P 2017-06-30 2017-06-30
US62/527,274 2017-06-30
PCT/US2018/040523 WO2019006440A1 (en) 2017-06-30 2018-06-30 MAGNETIC NANOPARTICLES FOR TARGETED ADMINISTRATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204132A Division JP2024028827A (ja) 2017-06-30 2023-12-01 標的化送達のための磁性ナノ粒子

Publications (2)

Publication Number Publication Date
JP2020527545A true JP2020527545A (ja) 2020-09-10
JP2020527545A5 JP2020527545A5 (https=) 2021-09-09

Family

ID=64742731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019572658A Pending JP2020527545A (ja) 2017-06-30 2018-06-30 標的化送達のための磁性ナノ粒子
JP2023204132A Pending JP2024028827A (ja) 2017-06-30 2023-12-01 標的化送達のための磁性ナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023204132A Pending JP2024028827A (ja) 2017-06-30 2023-12-01 標的化送達のための磁性ナノ粒子

Country Status (8)

Country Link
US (1) US20200146995A1 (https=)
EP (1) EP3645004A4 (https=)
JP (2) JP2020527545A (https=)
CN (1) CN111032023A (https=)
AU (1) AU2018291045A1 (https=)
BR (1) BR112020003956A2 (https=)
CA (1) CA3069671A1 (https=)
WO (1) WO2019006440A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515387A (ja) * 2021-04-30 2024-04-09 サムヤン ホールディングス コーポレイション 両親媒性高分子を含まないナノ粒子を含む薬物送達用組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4048290A4 (en) * 2019-10-22 2023-12-06 Otomagnetics, Inc. LIPID-COATED IRON OXIDE NANOPARTICLES FOR OTITIS MEDIUM
EP4054695A4 (en) * 2019-11-05 2024-01-03 Bionaut Labs Ltd. SYSTEM AND MINIATURE DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC CONSTITUENT AT A TREATMENT SITE IN A PATIENT
WO2021160873A1 (en) * 2020-02-13 2021-08-19 Eth Zurich Nanoparticles encapsulating small molecules
AU2021403179A1 (en) 2020-12-15 2023-08-03 Otomagnetics, Inc. Medical cart for magnetic treatment of middle ear conditions
WO2022236264A1 (en) 2021-05-04 2022-11-10 Otomagnetics, Inc. Methods for shaping magnetics fields to align forces on magnetic particles for patient anatomy and motion
CN115837078A (zh) * 2022-12-27 2023-03-24 西安超磁纳米生物科技有限公司 一种聚合物修饰的无机纳米材料冻干粉、制备方法及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096190A1 (en) * 2003-04-30 2004-11-11 Yonsei University Composition comprising magnetic nanoparticle encapsulating magnetic material and drug with biodegradable synthetic polymer
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US20070264199A1 (en) * 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
JP2013513661A (ja) * 2009-12-15 2013-04-22 ザ チルドレンズ ホスピタル オブ フィラデルフィア 治療用処方物の均一磁場による磁化および標的化
JP2013513616A (ja) * 2009-12-11 2013-04-22 バインド バイオサイエンシズ インコーポレイテッド 治療用粒子の凍結乾燥に対する安定製剤
JP2013527244A (ja) * 2010-06-04 2013-06-27 ハフ イヤ インスティテュート 内耳感覚有毛細胞の再生または置換のための組成物および方法
WO2013158549A1 (en) * 2012-04-20 2013-10-24 Board Of Regents Of The University Of Nebraska Small magnetite therapeutics and methods of use thereof
US20170151339A1 (en) * 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087586A1 (en) * 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
AU2004231992B2 (en) * 2003-04-16 2011-04-21 Drexel University Magnetically controllable drug and gene delivery stents
US20060204442A1 (en) * 2003-09-12 2006-09-14 Bankruptcy Estate Of Ferx, Inc. Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
KR101306641B1 (ko) * 2005-03-21 2013-09-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 작용화된 자성 나노입자 및 이의 사용방법
US20160346389A1 (en) * 2013-09-12 2016-12-01 Albert Einstein College Of Medicine Inc. Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
CN105434399B (zh) * 2015-12-24 2018-03-06 湖南尔康制药股份有限公司 一种肾细胞癌治疗药物舒尼替尼‑PLGA/Fe3O4复合微球及其制备方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096190A1 (en) * 2003-04-30 2004-11-11 Yonsei University Composition comprising magnetic nanoparticle encapsulating magnetic material and drug with biodegradable synthetic polymer
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US20070264199A1 (en) * 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
JP2013513616A (ja) * 2009-12-11 2013-04-22 バインド バイオサイエンシズ インコーポレイテッド 治療用粒子の凍結乾燥に対する安定製剤
JP2013513661A (ja) * 2009-12-15 2013-04-22 ザ チルドレンズ ホスピタル オブ フィラデルフィア 治療用処方物の均一磁場による磁化および標的化
JP2013527244A (ja) * 2010-06-04 2013-06-27 ハフ イヤ インスティテュート 内耳感覚有毛細胞の再生または置換のための組成物および方法
WO2013158549A1 (en) * 2012-04-20 2013-10-24 Board Of Regents Of The University Of Nebraska Small magnetite therapeutics and methods of use thereof
US20170151339A1 (en) * 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDRA RODZINSKI ET AL.: "Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles", SCIENTIFIC REPORTS, vol. Vol.6 article number:20867, JPN7022002109, 15 February 2016 (2016-02-15), pages 1 - 14, ISSN: 0005118629 *
XIN HUA ET AL.: "Externally Controlled Triggered-Release of Drug from PLGA Micro and Nanoparticles", PLOS ONE, vol. 9, no. 12, JPN7022002110, 5 December 2014 (2014-12-05), pages 1 - 17, ISSN: 0005118628 *
YOUDAN WANG ET AL.: "Incorporation, Release, and Effectiveness of Dexamethasone in Poly(Lactic-Co-Glycolic Acid) Nanopart", JOURNAL OF NANOTECHNOLOGY IN ENGINEERING AND MEDICINE, vol. Vol.2 Issue 1, JPN7022002108, 1 February 2011 (2011-02-01), pages 1 - 7, ISSN: 0005118627 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515387A (ja) * 2021-04-30 2024-04-09 サムヤン ホールディングス コーポレイション 両親媒性高分子を含まないナノ粒子を含む薬物送達用組成物
JP2024517766A (ja) * 2021-04-30 2024-04-23 サムヤン ホールディングス コーポレイション 薬物を含有し、両親媒性高分子を含まないナノ粒子製造用キット
JP7820409B2 (ja) 2021-04-30 2026-02-25 サムヤン ホールディングス コーポレイション 両親媒性高分子を含まないナノ粒子を含む薬物送達用組成物

Also Published As

Publication number Publication date
US20200146995A1 (en) 2020-05-14
JP2024028827A (ja) 2024-03-05
CN111032023A (zh) 2020-04-17
EP3645004A4 (en) 2021-05-05
CA3069671A1 (en) 2019-01-03
BR112020003956A2 (pt) 2021-08-03
AU2018291045A1 (en) 2020-02-13
EP3645004A1 (en) 2020-05-06
WO2019006440A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
JP2024028827A (ja) 標的化送達のための磁性ナノ粒子
Wu et al. Long-acting nanoparticle-loaded bilayer microneedles for protein delivery to the posterior segment of the eye
Karabasz et al. Biomedical applications of multifunctional polymeric nanocarriers: A review of current literature
Ahmed et al. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications
Roberts et al. Development of PLGA nanoparticles for sustained release of a connexin43 mimetic peptide to target glioblastoma cells
Koo et al. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection
ES2846809T3 (es) Métodos y composiciones relacionadas con el uso de tensioactivos de bajo HLB en la producción de nanovehículos sintéticos que comprenden un rapalogo
ES2447465T3 (es) Partículas de superficie modificada y métodos para la administración dirigida de fármacos
CN107115314B (zh) 膜包封的纳米颗粒及使用方法
Karumanchi et al. Rational design of liposomes for sustained release drug delivery of bevacizumab to treat ocular angiogenesis
US11090268B2 (en) Targeted hydrophobic anti-tumor drug nanoformulation and preparation method thereof
US11213490B2 (en) Encapsulation-free controlled protein release system
JP2014510724A (ja) 熱応答性ハイドロゲル組成物
Kim et al. Surgical suture releasing macrophage-targeted drug-loaded nanoparticles for an enhanced anti-inflammatory effect
EP2029119A2 (de) Funktionalisierte, feste polymernanopartikel für diagnostische und therapeutische anwendungen
WO2019195301A1 (en) Hydrogels with liposomes for controlled release of drugs
Yang et al. Intravitreal administration of dexamethasone-loaded PLGA-TPGS nanoparticles for the treatment of posterior segment diseases
CN104622817B (zh) 一种蛋白‑聚合物复合纳米载体及其制备方法
Du et al. Enhanced delivery of biodegradable mPEG-PLGA-PLL nanoparticles loading Cy3-labelled PDGF-BB siRNA by UTMD to rat retina
CN102579337A (zh) 含有多西他赛的长循环脂质纳米混悬剂及其制备方法
Suciati et al. A novel acemannan-chitosan modified lipid nanoparticles as intracellular delivery vehicles of antibiotic
CN109718202B (zh) 一种适用于载疏水性化学药物的靶向载药胶束
Ahmad et al. Applications of nanotechnology in pharmaceutical development
Li et al. Research Progress on the nano-delivery systems of antitumor drugs
CN104771373A (zh) 一种载药聚氰基丙烯酸烷酯纳米载体及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20211029

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230801

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251201